In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. ACADIA Pharmaceuticals Inc ...

Foundation Announces $60K Scholarship Fund with Miami Dade College to Expand Opportunities for Young Adults with Disabilities as They Transition to Adulthood The Supreme Twins Foundation – a nonprofit ...

WE’LL TALK TO YOU LATER. WELL, IMAGINE EATING ENOUGH MAYBE TOO MUCH, BUT NEVER FEELING FULL. THAT’S WHAT A NORTHLAND TODDLER LIVES WITH EVERY DAY. AND THIS WORLD WHERE DISEASE DAY CAME DECISIONS DONNA ...

How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin ...

Soleno Therapeutics (SLNO) stock falls as a patient who was receiving its rare disease drug Vykat XR dies, according to a ...

Then, on September 10, 2025, Soleno disclosed a patient death involving its Prader-Will Syndrome treatment, VYKAT XR, which ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...

The FDA granted orphan drug designation to an investigational drug for the treatment of Prader-Willi syndrome, according to an industry press release. Tesomet (Saniona) is an investigational, ...

Family genetics evaluations. Several family visits with the geneticist and subsequent laboratory evaluations revealed that Bobby had PWS. It was also established that his siblings did not have the ...

Soleno Therapeutics’ Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...